COVID19, COVID Vaccine, Pfizer, Moderna, Pandemic, Vaccine, Humanity, RNA

Pandemics, like wildfires, need to be extinguished quickly, otherwise they spiral out of control. Pfizer’s policies in regard to the allocation and pricing of its COVID-19 vaccine have brought the developing world to the brink of an enormous humanitarian catastrophe and has exposed rich countries to serious risks in the time to come.

COVAX: COVID vaccine for all

The entire world had endured the trauma of COVID–19 through all of 2020. It was plainly evident that when a vaccine became available, there would be a mad frenzy to get to the front of the line—a line of over five billion people.

Recognising this, the World Health Organisation, in partnership with GAVI, the Vaccine Alliance, had established COVAX in the spring of 2020 to ensure a “fair and equitable” distribution of vaccines to all countries. The essence of the plan was for COVAX to procure two billion doses of the COVID vaccine. It would provide the first 20 percent of each country’s requirements in 2021, to cover the most vulnerable people in all countries. It established prices of US $1, 2, and 3 per dose depending upon the income level of the recipient country.

Pfizer goes to town

Following the FDA approval of Pfizer’s vaccine on December 12, all hell broke loose. True to script, demand exploded and Pfizer quickly realised that it could sell as much of its vaccine at whatever price it chose to.

Pfizer established a price of US $20 per dose, 10 times that of the recommended median COVAX price. Even at this price, customers were literally begging for vaccines. PM Netanyahu of Israel boasted—not complained—that he had had to call Albert Bourla, the CEO of Pfizer, 17 times to ensure an allocation for Israel.

Another COVID vaccine was brought to the market at about the same time by Moderna. Unlike Pfizer, an established “Big Pharma” company, Moderna was just ten years old and had been founded by university professors. Moderna’s management was content to follow Pfizer’s leadership, without asking any awkward questions. In fact, after seeing the insatiable demand for Pfizer’s vaccine, it priced its (identical) vaccine at US $30, i.e., 50 percent higher than Pfizer’s rate, which also the customers lapped up happily. David Ricardo’s theory of scarcity rent was proven like never before in history.

Pfizer’s “sales strategy” was very simple: Sell to whoever can pay right away. Naturally, the rich countries promptly soaked up the supplies leaving everybody else in the lurch. The list of Pfizer’s customers was identical to the list of countries with the highest per capita GDP in the world. The 90+ developing countries have so far received virtually no vaccine from Pfizer.

Pfizer’s management will defend its actions on the basis of trying to “maximise shareholder interest”. This is convenient but only partly true. The real motivation is, in fact, trying to maximise executive management compensation. To illustrate, the CEO, Albert Bourla, earned a salary and bonus of about US $5.2 million last year, and US $10.4 million from stock options. And, this was before Pfizer had sold a single drop of its outrageously priced vaccine.

As of date, Pfizer has committed to contribute a mere 40 million doses of its vaccine to COVAX. This is only 2.5 percent of both COVAX’s requirements (2 billion) and also the annual capacity of Pfizer and its associates (also 2 billion).

Vaccines are public goods

Vaccine manufacturers, particularly in the US, have been provided generous financial and research support by the government and private foundations. This is, indeed, laudable.

The pioneering work on the mRNA technology, which is the foundation for both the Pfizer and Moderna vaccines, was done at the University of Pennsylvania. The extraordinary commitment of Katalin Kariko—an unsung lab technician—was central to the development of the mRNA technology. Her passion was the science, not the monetary rewards.

Pfizer received US $1.95 billion in financial support as an advance from the US government under the Operation Warp Speed programme. Ironically, the “Pfizer vaccine” was not even developed by Pfizer. It was developed by BioNTech, a German company founded by Turkish immigrants, which received a grant of 375 million euro from the German government and an investment of US $55 million from the Gates Foundation.

Donors of private foundations get tax benefits and to that extent their monies acquire the character of public funds.  Knowledge and products that are born out of public funds are public goods. Hence, vaccines are no exception. Providers of such monies, both government and private foundations, must ensure that the concept of public goods is clearly written into their financial arrangements. In the absence of this, the drug and vaccine development business becomes a convenient vehicle for funneling public funds to corporate shareholders. Professor Marianna Mazzucato eloquently summarised this state of affairs: “We have socialised the risks and privatised the rewards”.

A crisis of conscience

Let us, first of all, recognise that the entire world is waging a war—a war against the virus. We have lost more than 3 million people to the virus so far. And the virus is not done with us yet. While we keep talking about masks and social distancing, the virus continues its macabre dance—spreading, infecting, killing, mutating, and sowing grief—silently, mercilessly.

At the end of the day, we really have only one weapon in our arsenal to fight this diabolical virus: A vaccine. Pfizer and Moderna have deliberately denied millions of innocent people this very basic tool to prevent what is quickly becoming the worst tragedy in the history of mankind.

Over four months have elapsed since the vaccines were rolled out. Yet, over 40 countries have vaccinated less than 1.0 percent of their populations. This list includes large and important countries such as Nigeria, South Africa, Venezuela, Egypt, Ethiopia, Pakistan, Iran, Iraq, and Sudan. Broad vaccination coverage will not happen in the vast majority of these countries before the second half of 2022. Mr. Tedros, the Director General of the WHO, aptly summed up this state of affairs in just one word, “grotesque”.

To be sure, rich countries ordering vaccines far in excess of their per capita requirements must shoulder a good part of the blame for this horrific state of affairs. But it is abundantly clear where the primary responsibility for this calamity lies: Pfizer and Moderna. Specifically: They set prices that have absolutely no relationship to costs. Allocated product without the slightest consideration of the critical need to inject a certain degree of “fairness and equity” in the process. They made a minute contribution of just 2.5 percent to COVAX.

Directly, as a result of Pfizer’s reckless policies, humankind is paying an unprecedented price in terms of human health and completely avoidable deaths of large numbers of people. And, it will get far more brutal.

The perpetual pandemic 

There is cause for celebration in many countries. Disneyland is opening up, as are the pubs and West End in London. Restaurants and flight bookings are picking up. Spring is in the air. Finally.

But there is one underlying concern: Variants. It is through viral mutation that the most sinister variants survive and thrive, and the SARS-CoV-2 virus is no exception. Since the virus has already infected 150 million people, it has spun tens of millions of variants, many of them more lethal than the original virus.

In fact, this virus is waging an extreme form of guerilla warfare. Consider this: If you could capture all the SARS-CoV-2 viruses in the world, you could fit them in a single can of Coke. Yet, with all our guns, submarines, SAMs, nuclear weapons and, yes, intelligence, we are just unable to come to grips with this horrific enemy. And the virus respects neither the immigration officials nor border walls.

The variants are helped along by that most marvelous of human inventions—the airplane. Within days of the double mutant appearing in India, it was identified in France. The Brazilian variant is widespread in the US, and the South African and the UK (Kent) variants are, well, everywhere. Each of these variants has the potential to seed another, even more numbing pandemic than what we have witnessed so far.

This is great for the vaccine makers who are looking forward to developing new vaccines for every variant. The adage “No country is safe until every country is safe” is not just empty words. The risks for humanity are profound.

As Dr. Luciana Borio, the former Director for Medical and Biodefense Preparedness at the US National Security Council put it: “You can’t battle a pandemic with travel restrictions, unfortunately, which makes it so important to share vaccines with the world… before the virus gets to our shores.

By deliberately excluding the very poor from accessing vaccines, Pfizer and Moderna have set the stage for not just the poor but also their rich and famous clients to live under the Damocles sword of a perpetual pandemic for several years.

It is possible that the horror movie we are seeing in India will play out in some form or the other in many, many other countries before we can declare victory against this diabolical pathogen.

**Arun Jain was, until recently, a member of the Board of Directors of the WHO Foundation. The views expressed are solely those of the writer. Neither the WHO nor the WHO Foundation has had any advance intimation about this essay.

This article has been revised and updated for clarity and in response to reader comments. 

The views expressed above belong to the author(s).

ORF research and analyses now available on Telegram! Click here to access our curated content — blogs, longforms and interviews.


Covid-19: What US, China data tell us about children’s risk profile

Covid-19: Impact on Africa

Covid-19 pandemic-pandemonium: Need for a more holistic idea of disaster management

Nigeria must not forget its poor in the Covid-19 world

No, China isn’t winning the virus propaganda battle

Mauritius: Old and new challenges in a post-pandemic world

A global comparison of COVID-19 deaths: How is India doing in counting its sick and dead?

How China overcame the Covid-19 pandemic

Amid Covid-19 crisis, its politics as usual in Slovenia

Redefining the development narrative during Covid-19: The private sector perspective

A global pandemic and globalisation

Technology and business order post COVID-19

France facing Covid-19: growing pressure on the public health system

COVID19: What we’ve learnt from New York’s deadliest week

The circuit breaker: Singapore’s next move in its fight against COVID-19

American bioweapon or the ‘China Virus’? The war of words over COVID-19

Coexisting with #Covid19: Saving lives and the economy

The wrong diagnosis

Covid-19: China’s donation diplomacy towards Africa turns into a public relations disaster

COVID19: The Chinese military is busy exploiting the pandemic

Mitigating risks and adjusting to isolation: How Argentina is dealing With Covid19

Covid-19: The perfect storm for deep reform

#Covid19: For now, lives over livelihoods

How a changing global order will emerge in the post-Covid world

The Caribbean region must come together to fight Covid19

Politics of pandemic: Public health can no longer wait

Georgia goes all out in fight against Covid19

COVID19: A boost for Indian labour in the global market

Armed Forces and the Covid19 pandemic

Bhutan’s preparedness and response to COVID19

Economic recovery and recurring lockdown in China after Covid19 crisis

Public transit in post COVID19 India: where do we go from here

Critiquing Amartya Sen’s contention of post-lockdown society

Post pandemic city planning

Could third world countries seek a new world order in Covid19 aftermath?

Economic vulnerabilities and power shifts in a post-Covid19 world

Opportunity in Crisis: Will a pandemic lead to peace with the Taliban in Afghanistan? 

Health Policy belongs to the national security domain and different stakeholders must engage

Can the global economy survive COVID19 shocks?

The COVID19 reality of Afghanistan

Changing the script

Leadership in the time of Corona

PM’s India shutdown is an unprecedented gamble

COVID19: Tamil Nadu’s demand for fiscal grant can put centre in a fix

COVID19 brings Australia to the crossroads

The battle to set oil prices

Luxembourg faces the same dilemma as the EU: become a bridge or a fortress

Peace during a pandemic: The US fumbles on in Afghanistan

Crisis communication and the Coronavirus contagion

COVID-19 and maritime operations

How PM Modi scored with COVIDiplomacy

Covid-19: The crisis will strengthen anti-globalisation voices

An old scourge in a new, uncertain age

To what extent will coronavirus outbreak rewire global trade dynamics?

The Chinese model is under stress

A sneeze, a global cold and testing times for China

Corona: The case for taking China to ICJ

Covid-19, India and crisis communication

How Is COVID-19 reshaping China-India relations?

France must confront the grim realities of its war against COVID 19

Covid19: G20 leaders reclaim power from bureaucrats – and China

The United Nations Security Council and securitization of COVID-19

Mexico can teach us COVID 19 management

Covid-19 and European solidarity: The fight for who we are

Dr WHO and Mr Hyde

Certified Corona-Immunity as a resource and a way back to normality

Coronavirus derails Glasgow

Food security and the Corona Virus

The Polish example: Defending the castle in the European East

COVID19: Americans brace for brutal week against grim backdrop of chaotic policymaking

SOS for the road transport sector at the time of CoVid19 pandemic

Despite Coronavirus outbreak, India-Israel friendship continue to shine

COVID-19 and international collaboration in a leaderless world

Covid-19: A report from Nigeria

As Dubai EXPO 2020 is postponed, a tough time for NRIs

The virtual space uptick during Covid-19

OECD, BRICS Countries must mitigate Covid-19 fallout through targeted measures

A new human being will emerge in the post-Covid-19 world

Ravaged by war, Cameroon’s Southwests region turns attention to Covid-19 fight

What India needs on 14 April

Covid-19 crisis and a probable role for the Indian Military

COVID-19 and the gameplay of West Asia’s geopolitics

Covid19 has sharpened great power politics

Liechtenstein’s national and international response to COVID19

Why China and Pakistan need each other in the Covid19 crisis

Diplomacy is another victim of the virus

Gated globalisation and fragmented supply chains

West Asia is staring at an economic crisis. India has to be prepared

Fishing in troubled waters during a pandemic

Xi’s moves seem to be backfiring

Iran’s grim fight against coronavirus

Why is the Covid 19 situation so grim in MP?

Hacking the pandemic : Lessons from the Silicon valley of India

Between firmness and hesitation: How Russia is responding to the COVID19 challenge

World after Covid19 pandemic

Israel must bring its diverse communities together in Covid19 fight

China tightens grip over the South China Sea – should India worry?

Nod, Nudge, (K)nock out: Ways for RBI to prompt banks to lend

Will Covid19 crisis hasten the end of PM Abe’s regime?

Covid19: China-Russia make strategic geopolitical moves in Italy

Leadership accountability for Covid19 and the reasons for WHO’s apathy

Maldives: Amidst worsening Covid19 crisis, ISIS ‘claims maiden attack’

The impact COVID19 pandemic is exerting on e-commerce

COVID19 and competition for influence in South Asia

Examining India’s employment landscape amidst the COVID19 disruptions

Will COVID19 crisis rejuvenate the coalition of SAARC nations

The future of international cooperation in times of existentialist crises

Rebooting Ramadan for COVID19 times: With tech but without Iftar parties

COVID19’s impact on India’s solar industry

Reset in EU-China relations tougher in a post Covid19 world

India fires a salvo at China

Bend it like Kerala: How an Indian state is holding its own against COVID19

Post covid stimulus for clean energy: Govt must focus on developing an EV ecosystem

Women leaders and alpha males up against Covid19

East Africa and Kenya under the COVID19 emergency

Can ‘Advance manufacturing’ change the game in India-Australia relationship

International trade and environment sustainability: The two must tango

Fiscal prudence still matters

Maldives: Evacuation, yet another-milestone in bilateral ties

2020 could be to Narendra Modi what 1991 was to P.V. Narasimha Rao: a lasting legacy

China’s salami slicing overdrive

Rolling up the welcome mat for Chinese investors

China’s assertive behavior in the South China Sea and the implications for India

Xi Jinping: A matter of state security

How growth and equity get a boost in Finance Minister’s economic stimulus package

Why is China building its nuclear arsenal as world fights COVID?

Keep Hobbes at bay whilst Covid is at play

Nepal: Challenges of reviving economy, post-Covid

The pandemic and China are strengthening US-India relations, for now

The trends shaping the post-COVID19 world

How the pandemic is an opportunity to create a ‘more equal’ world

COVID19 and the middle power moment in global politics

Coronavirus is straining the concept of federalism

Infections, Islamophobia, and intensifying societal polarization

Government is being cautious, and that’s sensible

Covid19 and implications on global health governance

Community model from rural Maharashtra to combat Covid19

Covid19: The birth of a new power

Biological Weapons and Biosecurity – Lessons from the COVID19 war

What can we learn from the genomes of the novel coronavirus?

What India’s digital divide means for migrant workers in a COVID19 world and beyond

COVID19 has hit Africa’s amateur athletes

Exiting the ‘COVID chakravyuh’ through a bioethics prism

Guiding democracy through Covid19: Poland shows us what not to do

Rethink, Revive, Rescue: From the Pandemic to Multilateralism 2.0

Return of the migrants

Covid19 is reshaping Brazil’s politics

Vietnam emerges victorious in fight against Covid19

How Georgia tackled Covid19 bit by bit

The potential fallouts of EU’s collective response to COVID19

Covid19 has forced us to think about building a remote working culture

How Bangladesh is addressing the Covid19 pandemic

Covid reality: Cost of human lives and how to fund healthcare

Walled city dilemmas in the fight against COVID19: The case of Ahmedabad

Viral load matters: Frontline healthcare workers 11% of US COVID19 cases

Sustained shift to virtual classrooms may not be a good idea for India

Cooperation of consequence: Lessons from the 2004 tsunami response in the era of COVID19

COVID, oil collapse and economic contraction: Can the low carbon transition be salvaged?

Antibody tests not useful for back-to-work policy decisions: Expert

Risks of putting all eggs in China basket

Mumbai in numbers

Every policy change does not a reform make

Reviving the Indian economy- revisiting Mr. Keynes

India needs to win back the third world’s trust

Epidemic in China and the world: Public health, earth science and geopolitics

COVID-19: China’s ‘Health Silk Road’ diplomacy in Iran and Turkey

China’s footprint is growing within the United Nations

Russian response to Covid-19: The challenges ahead

Inter-species spillover of viruses: Understanding zoonosis and India’s future concern

Nature, politics and Covid-19

The real journey of Hydroxychloroquine

The economic cost of COVID19 is bigger than the great depression

To die hungry or die sick

US-India cooperation against COVID19

Towards a quad-plus arrangement

Will the coming monsoons result in a spike in COVID19 cases in India?

Covid19 and Conflict in Myanmar: No Truce for the Rohingya

Perspectives on SARS-CoV-2 strains

COVID19 and the acceleration of digital transformations in maritime logistics

  • May 22 2020

How the Visegrád group countries have managed the Corona crisis

Lockdown: uncertain gains, rising losses

Covid Corrections: How the Pandemic Reveals the Failures of India’s Growth Model

COVID19: Public health is a question of national security

Understanding the coming challenges to India’s pharma sector

Lockdowns, curfews and prayer: Exploring East African countries’ COVID19 response

WHO, the battleground for cold war 2.0

Covid-19 and emerging economies: What to expect in the short- and medium-term

The Good, the Bad, and the Ugly: Germany’s response to the COVID-19 Pandemic